Outset Medical, Inc. (OM) Stock Price & Analysis
Outset Medical, Inc. (OM) rose 8.56% to USD 4.69 as of June 10, 2026 at 02:15 UTC, according to Nexqual real-time market data.
OM last closed at USD 4.32; the session ranged USD 4.37–4.8 on volume of 192,688 shares. Market capitalization is $86.94M, with a 52-week range of USD 3–21.36 (NMS). Source: Nexqual, June 10, 2026 at 02:15 UTC.
Key Statistics (as of June 10, 2026 at 02:15 UTC)
| Price | USD 4.69 |
|---|---|
| Change | ▲ 8.56% (up) |
| Previous Close | USD 4.32 |
| Open | USD 4.38 |
| Day Range | USD 4.37 – 4.8 |
| 52-Week Range | USD 3 – 21.36 |
| Volume | 192,688 shares |
| Market Cap | $86.94M |
| Exchange | NMS |
Technical Analysis (OM)
Nexqual's technical model rates OM "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:15 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 53.56 (neutral) |
| vs SMA50 | Above (USD 4.31) |
| MACD | 0.14 (positive) |
Analyst Ratings (OM)
Wall Street analysts rate OM "None" based on 3 analysts, with a mean price target of USD 8.33 (range USD 7–10), per Nexqual as of June 10, 2026 at 02:15 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 8.33 |
| High Target | USD 10 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (OM)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.72 |
| Revenue Estimate | $29.83M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.83 vs est -0.79 ▼ miss |
| 2025-12-31 | USD -0.84 vs est -0.68 ▼ miss |
| 2025-09-30 | USD -0.69 vs est -0.66 ▼ miss |
| 2025-06-30 | USD -0.84 vs est -0.98 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financials & Fundamentals (OM)
| Total Revenue | $117.59M |
|---|---|
| Revenue Growth (YoY) | -6.30% |
| Gross Margin | +40.64% |
| Operating Margin | -60.72% |
| Profit Margin | -63.65% |
| ROE | -53.17% |
| Debt / Equity | 90.98 |
| Current Ratio | 6.29 |
| Total Cash | $156.71M |
| Total Debt | $101.61M |
| Free Cash Flow | $-10.46M |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Financial Health Score (OM)
Nexqual rates Outset Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:15 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 41%, operating -61% |
| Balance Sheet | Mixed — $157M cash vs $102M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -53%, ROA -15.3% |
Ownership (OM)
| Insider Ownership | +3.65% |
|---|---|
| Institutional Ownership | +84.18% |
| Shares Outstanding | 18.54M |
| Float | 15.48M |
| Short % of Float | +16.30% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
Leadership (OM)
Outset Medical, Inc. is led by Leslie L. Trigg (age 54), President, CEO & Chairman, per Nexqual as of June 10, 2026 at 02:15 UTC.
| President, CEO & Chairman | Leslie L. Trigg (age 54) |
|---|---|
| CFO, Principal Financial Officer & Principal Accounting Officer | Renee M. Gaeta (age 44) |
| Vice President of Corporate Communications & Investor Relations | James S. Mazzola |
| Senior Vice President of Regulatory Affairs & Quality Assurance | Dinamarie Stefani |
| Senior Vice President of R & D & Operations | Brett Fogg |
Major Backers & Investors (OM)
Notable institutional backers of Outset Medical, Inc. include FMR, LLC, Fidelity, BML Capital Management, LLC, according to Nexqual as of June 10, 2026 at 02:15 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.79% |
| Fidelity | 13.92% |
| BML Capital Management, LLC | 10.26% |
| Bank of America Corporation | 5.12% |
| Perceptive Advisors Llc | 4.5% |
| AQR Capital Management, LLC | 4.36% |
| Pfm Health Sciences, Lp | 3.21% |
| Ensign Peak Advisors, Inc | 2.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.44% |
| Vanguard Group | 8.13% |
Source: Nexqual, June 10, 2026 at 02:15 UTC.
From Outset Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States.
- The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
- It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LUNG | Pulmonx Corporation | USD 1.53 | ▲ 0% |
| LOB | Live Oak Bancshares, Inc. | USD 38.63 | ▲ 3.26% |
| FTHM | Fathom Holdings Inc. | USD 0.46 | ▼ 7.19% |
| DCBO | Docebo Inc. | USD 17.82 | ▲ 3.54% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.94 | ▲ 3.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:15 UTC. This page is informational and not investment advice.